Incyte (INCY) Research | Aerarium Research

Forward Estimates

EPS Estimates

Current Qtr

$1.82

$1.51$1.99

vs $1.57+16.2%

19 analysts

Next Qtr

$2.00

$1.72$2.21

vs $2.26-11.5%

18 analysts

Current Yr

$7.69

$6.81$8.08

vs $6.80+13.1%

23 analysts

Next Yr

$9.07

$7.63$11.15

vs $7.69+17.9%

22 analysts

Revenue Estimates

Current Qtr

$1.37B

$1.32B$1.44B

vs $1.22B+12.6%

19 analysts

Next Qtr

$1.45B

$1.42B$1.52B

vs $1.37B+6.3%

19 analysts

Current Yr

$5.62B

$5.51B$5.82B

vs $5.14B+9.4%

23 analysts

Next Yr

$6.24B

$5.75B$7.45B

vs $5.62B+11.0%

23 analysts

SEC filings →

View all 10-K, 10-Q, and 8-K filings for INCY on EDGAR.

INCY filing events and research context
Filed	Item	Context
Feb 10, 2026	mda	Incyte reported a significant increase in net income to $1.29 billion in 2025, primarily driven by JAKAFI revenues of $3.09 billion and the successful first-quarter launch of NIKTIMVO. Despite this growth, the company faces a critical revenue risk as JAKAFI patent exclusivity expires in 2028, necessitating the commercial success of other products, such as OPZELURA and ZYNYZ, to offset the expected decline. A major financial event in 2025 was the settlement with Novartis, which required a $280 million payment but reduced future U.S. JAKAFI royalty rates by 50%. Additionally, Incyte recorded a $76.3 million asset impairment charge related to Wilmington properties now classified as held for sale. The company maintains a strong liquidity position with $3.6 billion in cash, cash equivalents, and marketable securities. Strategic R&D remains focused on Hematology, Oncology, and Inflammation and Autoimmunity. Financial results are further influenced by the Inflation Reduction Act’s Medicare Part D changes and the One Big Beautiful Bill Act, the latter of which materially reduces U.S. tax liabilities through the expensing of domestic research costs.
Feb 10, 2026	risk_factors	Incyte faces significant concentration risk due to its heavy reliance on JAKAFI (ruxolitinib), with revenues expected to decline following patent expiration in 2028. The company is currently defending JAKAFI and OPZELURA against Paragraph IV generic challenges from multiple manufacturers. Financial performance is further pressured by the Inflation Reduction Act’s impact on Medicare reimbursement and potential "most favored nation" pricing policies. Operational vulnerabilities include a high dependence on third-party contract manufacturers, particularly for active pharmaceutical ingredients sourced from China, and a concentration of R&D operations in Wilmington, Delaware. Regulatory risks are underscored by FDA "boxed" warnings for JAK inhibitors regarding cardiovascular events and malignancies, which may limit the commercial potential of JAKAFI and OPZELURA. Additionally, Incyte’s growth depends on the successful clinical progression of its pipeline and the stability of collaboration agreements with partners like Novartis and Eli Lilly for assets such as TABRECTA and OLUMIANT. Failure to secure broad third-party payor coverage or the loss of key specialty pharmacy distributors could further impair financial results. Finally, the company remains exposed to the inherent uncertainties of late-stage clinical trials and the rigorous requirements for obtaining global regulatory approvals.
Feb 10, 2025	business	Incyte operates in the oncology and dermatology markets, with primary revenue drivers JAKAFI and OPZELURA. The company maintains critical collaborations with Novartis for JAKAVI and TABRECTA, and Lilly for OLUMIANT. A significant financial risk is the threat of generic entry; Apotex has challenged patents for JAKAFI (expiring 2028), and Padagis has challenged OPZELURA patents. Incyte is currently litigating against Sun Pharmaceutical over the launch of Leqselvi, having secured a preliminary injunction in November 2024. Regulatory hurdles include the withdrawal of the parsaclisib NDA and complete response letters for ruxolitinib XR. Operationally, Incyte relies heavily on third-party contract manufacturers and single-source raw materials for JAKAFI, creating supply chain vulnerabilities. Financial performance is further pressured by the Inflation Reduction Act’s price negotiation provisions and Medicaid rebate changes. The company’s long-term growth depends on diversifying its portfolio through the commercialization of PEMAZYRE, MONJUVI, ZYNYZ, and NIKTIMVO, as well as continuing R&D investment despite the inherent risks of clinical trial failures and the high cost of drug discovery.

Filed

Item

Context

Feb 10, 2026

mda

Incyte reported a significant increase in net income to $1.29 billion in 2025, primarily driven by JAKAFI revenues of $3.09 billion and the successful first-quarter launch of NIKTIMVO. Despite this growth, the company faces a critical revenue risk as JAKAFI patent exclusivity expires in 2028, necessitating the commercial success of other products, such as OPZELURA and ZYNYZ, to offset the expected decline. A major financial event in 2025 was the settlement with Novartis, which required a $280 million payment but reduced future U.S. JAKAFI royalty rates by 50%. Additionally, Incyte recorded a $76.3 million asset impairment charge related to Wilmington properties now classified as held for sale. The company maintains a strong liquidity position with $3.6 billion in cash, cash equivalents, and marketable securities. Strategic R&D remains focused on Hematology, Oncology, and Inflammation and Autoimmunity. Financial results are further influenced by the Inflation Reduction Act’s Medicare Part D changes and the One Big Beautiful Bill Act, the latter of which materially reduces U.S. tax liabilities through the expensing of domestic research costs.

Feb 10, 2026

risk_factors

Incyte faces significant concentration risk due to its heavy reliance on JAKAFI (ruxolitinib), with revenues expected to decline following patent expiration in 2028. The company is currently defending JAKAFI and OPZELURA against Paragraph IV generic challenges from multiple manufacturers. Financial performance is further pressured by the Inflation Reduction Act’s impact on Medicare reimbursement and potential "most favored nation" pricing policies. Operational vulnerabilities include a high dependence on third-party contract manufacturers, particularly for active pharmaceutical ingredients sourced from China, and a concentration of R&D operations in Wilmington, Delaware. Regulatory risks are underscored by FDA "boxed" warnings for JAK inhibitors regarding cardiovascular events and malignancies, which may limit the commercial potential of JAKAFI and OPZELURA. Additionally, Incyte’s growth depends on the successful clinical progression of its pipeline and the stability of collaboration agreements with partners like Novartis and Eli Lilly for assets such as TABRECTA and OLUMIANT. Failure to secure broad third-party payor coverage or the loss of key specialty pharmacy distributors could further impair financial results. Finally, the company remains exposed to the inherent uncertainties of late-stage clinical trials and the rigorous requirements for obtaining global regulatory approvals.

Feb 10, 2025

business

Incyte operates in the oncology and dermatology markets, with primary revenue drivers JAKAFI and OPZELURA. The company maintains critical collaborations with Novartis for JAKAVI and TABRECTA, and Lilly for OLUMIANT. A significant financial risk is the threat of generic entry; Apotex has challenged patents for JAKAFI (expiring 2028), and Padagis has challenged OPZELURA patents. Incyte is currently litigating against Sun Pharmaceutical over the launch of Leqselvi, having secured a preliminary injunction in November 2024. Regulatory hurdles include the withdrawal of the parsaclisib NDA and complete response letters for ruxolitinib XR. Operationally, Incyte relies heavily on third-party contract manufacturers and single-source raw materials for JAKAFI, creating supply chain vulnerabilities. Financial performance is further pressured by the Inflation Reduction Act’s price negotiation provisions and Medicaid rebate changes. The company’s long-term growth depends on diversifying its portfolio through the commercialization of PEMAZYRE, MONJUVI, ZYNYZ, and NIKTIMVO, as well as continuing R&D investment despite the inherent risks of clinical trial failures and the high cost of drug discovery.

Forward Estimates

INCY filing events and research context

Keep researching INCY

Related tickers

Related explainers

Forward Estimates